You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.
ImiDomics has developed a platform that analyzes clinical and molecular data derived from an immune-mediated inflammatory disease biobank.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
The firm said that the new funds will enable it to build on the continued commercial expansion of its first product, PredictSure IBD, in the coming months.
In Nature this week: Integrative Human Microbiome Project researchers investigate host-microbiome relationship in health and disease, and more.
Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.
Life Genomics will distribute Luxia's 1test1 test in Sweden, Denmark, Finland, Iceland, and Norway. The test leverages sequencing technology to analyze the 16s RNA gene.
In Science this week: global transcriptome analysis of inflammatory bowel disease, and more.
The partners aim to determine whether the microbiome can be used to predict patient responses to certain inflammatory bowel disease therapies.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.